Of note, as TIM3, but not genes encoding other well‐known exhaustion markers such as PD‐1, CTLA4, LAG3, or TIGIT, was expressed at higher levels in TP53‐mutated AML than in controls, it could suggest that blockade of TIM3 is of specific clinical relevance for boosting T‐cell activity in this patient group. Here, TP53 is linked to acute myeloid leukemia.